12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alprolix rFIXFc regulatory update

Biogen Idec said FDA extended by 3 months the PDUFA date for a BLA for Alprolix rFIXFc to treat hemophilia B. According to the company, the delay was due to the submission of additional information on the validation of a manufacturing step for the recombinant fusion protein consisting of human coagulation...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >